Post-Traumatic Stress Disorder (PTSD) Market Research Report - Global Forecast till 2027

Post-Traumatic Stress Disorder (PTSD) Treatment Market Research Report: By Treatment (Psychotherapy (Cognitive Therapy, Exposure Therapy, Eye Movement Desensitization and Reprocessing (EMDR)), Medication, Antidepressants (Paroxetine, Sertraline, Mirtazapine, Amitriptyline or Phenelzine), Anti-Anxiety Medications (Beta-Blockers, Benzodiazepines), Prazosin)), By End User (Hospitals and Clinics, Ambulatory Surgical Centers) – Forecast to 2027

ID: MRFR/HC/6904-HCR | February 2021 | Region: Global | 100 pages

Post-Traumatic Stress Disorder Market Overview


Based on the ongoing trends and demand for the market products and services, the key industry leaders and market experts predict that the global post-traumatic stress disorder (PTSD) market is likely to grow at a CAGR of 4.8% during the ongoing forecast period of 2021-2028. The market is expected to reach a final revenue figure worth USD 1,380 million by the end of the forecast period in 2028.


 


Market partnerships and collaborations are on that are creating an excellent platform for the new entrants in the global market during the region. The prevalence of post-trauma stress disorder at a higher rate will help the post-traumatic stress disorder market grow at a good rate during the period.


 


COVID 19 Analysis of Post-Traumatic Stress Disorder Market


Due to the occurrence of the COVID 19 pandemic, various markets, and their players have witnessed a declined demand, and further, the supply chain mechanism that was running smoothly before has been disrupted, as well. The imposed restrictions and lockdown have resulted in the skilled labor to leave their jobs and opt for alternate means and further, the lack of resources and supportive amenities to keep up with the production trends is also hampering the post-traumatic stress disorder market from growing during the period.


 


Hence, as the restrictions are being lifted, the market players are running high on investment and helping in the development of the research and development departments. Also, the governments are playing a key role in helping the market revive its growth and demand. They are formulating regulations and schemes that will help the players grow at an ideal rate during the forecast period.


 


Post-Traumatic Stress Disorder Market Dynamics


Drivers


There has been a massive rate of product launches because traumatic stress is being addressed and considered on the global map. This is one of the main reasons why treatment is being demanded and hence, the market will grow at an excellent rate during the forecast period that ends in 2028. In August 2018, a prominent market player Sun Pharmaceutical Industries Limited announced that they will be launching a novel drug named Kapspargo Sprinkle in the US market, as a part of the North American region. This will help the patients that are suffering from hypertension, heart failure and for its recognized use for patients suffering from PTSD symptoms.


Restraints


However, one of the major issues that the post-traumatic stress disorder market is facing is to revive its demand and growth during the ongoing forecast period of 2021-2028 is the lack of information and awareness that is affecting the potential demand for the market. Also, the high price attached to the market products and limited availability will hamper the market operations during the period.


 


Technology Analysis


The key market players like the production sectors and the manufacturers are on the way to lay their focus on developing new products and making the best use of the available technology. There has been an increase in the adoption rate followed by the accessibility of antidepressants drugs in healthcare centers and hospitals. Janssen Pharmaceuticals is a subsidiary of Johnson and Johnson announced on March 27, 2018, the launch of the antidepressant nasal spray with the name of Spravato got the fast approval of USFDA. These are known to be a conjunction with an oral antidepressant.


 


Study Objectives



  • One of the major objectives of carrying out the market study and research is to understand the impact of the COVID-19 pandemic on the post-traumatic stress disorder market operations and thus, have an idea about the market dynamics in the form of drivers and restraints that will help the market move forward as per the predictions during the forecast period that ends in 2028.

  • To have an idea about the market functioning and the global market segmentations that are playing an important role in maintaining a proper supply chain mechanism based on the demands put forwards by the target audience in various global regions during the forecast period of 2021-2028.

  • To help the market investors take better and qualitative investment decisions by understanding the rising competitive degree and profitability quotient of the market players that are functional in the post-traumatic stress disorder market on a global scale.


 


Post-Traumatic Stress Disorder Market Segmentation


The post-traumatic stress disorder market has been divided all across the globe based on the treatment, end-user, and region.


Based on the Treatment


The post-traumatic stress disorder market has been divided all across the globe based on the treatment into prazosin, anti-anxiety medications, psychotherapy, medications, and many others.


Based on the End-Users


The post-traumatic stress disorder market has been divided all across the globe based on the end-users into ambulatory surgical centers, hospitals, clinics, senior citizen centers, home care, and others.


Based on the Region


Post-traumatic stress disorder (PTSD) has been associated with being divided in the global market based on the region into North American region, European region, Asia-Pacific region, Latin American region, and the Middle East and African region.


Post-Traumatic Stress Disorder Market Regional Analysis


The post-traumatic stress disorder market has been divided all across the globe based on the region into the North American region, Asia-Pacific region, European region, Latin American region, and the Middle East and African region. The largest market share in the global market is held by the North American region owing to increasing cases of stress disorders associated with various traumatic events like childhood physical abuse, sexual molestation, combat exposure, physical attack, childhood neglect, and rape and hence it drives the market demand in this region.


The second-largest market share in the global market is held by the European region owing to increasing human rights problems like sexual violence among women that has long and short term consequences and hence drives the market demand. Moreover, increasing research and development done by various major key players is another driving factor.


Being the fastest-growing region, the third-largest market share is held by the Asia-Pacific region owing to the presence of highly populous countries like China and India which results in an increased number of road accidents and various other traumatic events and hence drives the market demand in this region.


The Latin American region and the Middle East and African region also show a steady growth rate during the forecasted period owing to increasing healthcare expenditure, better adoption rate, presence of advanced technology, increasing government initiatives, and presence of optimal treatment facilities that drive the market demand to this region.


Competitive Landscape


The most prominent key players in the post-traumatic stress disorder market all across the globe are mentioned below:



  • Mylan NV (US)

  • Greenstone LLC (US)

  • Bionomics (Australia)

  • Tonix Pharmaceuticals Holding Corp. (US)

  • Marinus Pharmaceuticals, Inc. (US)

  • Azevan Pharmaceuticals (US)

  • Lundbeck A/S (Denmark)

  • Eli Lily and Company (US)

  • Pfizer (US)

  • GlaxoSmithKline (UK)


These major key players use various strategies to support their market position in the post-traumatic stress disorder market in the global market by going for mergers, and acquisitions, by collaborating, setting up a new joint venture, establishing a partnership, developing a new product line, innovation in the existing product, developing a unique production process, and many others to expand their customer base in the untapped market of the post-traumatic stress disorder market all across the globe.


Recent Developments



  • In 2017, the largest market share in the global market is held by the North American region. About 7.8% of the population is suffering from post-traumatic stress disorders out of which 5% were men and 10.4% were women. Around 5.2 million people aged between 18-54 suffered from these issues.

  • In 2015, sexually violent crimes had increased manifolds in the European region. It was recorded to be 215,000 out of which approximately 80,000 were rape cases. This increases post-traumatic stress disorders in women.

  • Marinus Pharmaceuticals, Inc. (US) is spending considerable money on research and development to get an upper edge over its competitors. This will help the company on enhancing its sales revenue.

  • The major market key players are highly investing in mergers and acquisitions, joint ventures, and new products.


Report Overview


The global post-traumatic stress disorder market research report holds the following components mentioned below:



  • Market Overview

  • COVID 19 Analysis

  • Market Dynamics

  • Technical Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Landscape

  • Recent Developments


This market research report contains factors that drive the growth of the post-traumatic stress disorder market in the global market and the factors that restrict its growth in the global market. The technical analysis in the global market during the forecasted period is mentioned. The impact of COVID 19 on the post-traumatic stress disorder market all across the globe is mentioned. The future growth rate in the post-traumatic stress disorder market during the forecast period is predicted, as well.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 7.3 Billion
  • 2027: Significant Value
  •   CAGR   4.8% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units    Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Treatment, End-User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Azevan Pharmaceuticals (US), Marinus Pharmaceuticals, Inc. (US), Bionomics (Australia), Greenstone LLC (US), GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), H. Lundbeck A/S (Denmark), Tonix Pharmaceuticals Holding Corp. (US), and Mylan NV (US)
      Key Market Opportunities

  • Increasing cases of cross-border tensions and violence- PTSD
  • Rising sexual assault cases
  •   Key Market Drivers

  • Rising prevalence of PTSD
  • The rising number of emerging therapies for PTSD treatment
  • An increasing number of clinical trials
  • Increasing rehabilitation programs for injured military personnel Rising incidences of road accidents
  • Launch of a new medication to manage the symptoms of post-traumatic stress disorder
  • A growing number of initiatives by public and private organizations


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    The post-traumatic stress disorder market valuation would be USD 7.3 billion by 2025.

    The CAGR for post-traumatic stress disorder market would be 4.8% during the forecast period.

    The hospitals & clinics segment has the largest post-traumatic stress disorder market segment.

    The Americas would dominate post-traumatic stress disorder market.

    The Asia Pacific post-traumatic stress disorder market would be the fastest-growing regional market.

    Table of Contents

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment

    6.1 Introduction

    6.2 Psychotherapy

    6.2.1 Cognitive therapy

    6.2.2 Exposure therapy

    6.2.3 Eye movement desensitization and reprocessing (EMDR)

    6.3 Medication

    6.3.1 Antidepressants

    6.3.1.1 Paroxetine

    6.3.1.2 Sertraline

    6.3.1.3 Mirtazapine

    6.3.1.4 Amitriptyline or phenelzine

    6.3.2 Anti-anxiety medications

    6.3.2.1 Beta-blockers

    6.3.2.2 Benzodiazepines

    6.3.3 Prazosin

    Chapter 7. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User

    7.1 Introduction

    7.2 Hospitals and Clinics

    7.3 Ambulatory Surgical Centers

    7.4 Others

    Chapter 8. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region

    8.1 Introduction

    8.2 Americas

    8.2.1 North America

    8.2.1.1 US

    8.2.1.2 Canada

    8.2.2 Latin America

    8.3 Europe

    8.3.1 Western Europe

    8.3.1.1 Germany

    8.3.1.2 France

    8.3.1.3 Italy

    8.3.1.4 Spain

    8.3.1.5 UK

    8.3.1.6 Rest of Western Europe

    8.3.2 Eastern Europe

    8.4 Asia-Pacific

    8.4.1 Japan

    8.4.2 China

    8.4.3 India

    8.4.4 Australia

    8.4.5 South Korea

    8.4.6 Rest of Asia-Pacific

    8.5 Middle East & Africa

    Chapter 9. Competitive Landscape

    9.1 Introduction

    9.2 Market Share Analysis

    9.3 Key Developments & Strategies

    9.3.1 Key Developments

    Chapter 10 Company Profiles

    10.1 GlaxoSmithKline

    10.1.1. Company Overview

    10.1.2. Financial Overview

    10.1.3. Products Offered

    10.1.4. Key Developments

    10.1.5. SWOT Analysis

    10.1.6. Key Strategies

    10.2 Pfizer

    10.2.1 Company Overview

    10.2.2 Financial Overview

    10.2.3 Products Offered

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.2.6 Key Strategies

    10.3 Eli Lilly and Company

    10.3.1 Company Overview

    10.3.2 Financial Overview

    10.3.3 Products Offered

    10.3.4 Key Developments

    10.3.5 SWOT Analysis

    10.3.6 Key Strategies

    10.4 H. Lundbeck A/S

    10.4.1 Company Overview

    10.4.2 Financial Overview

    10.4.3 Products Offered

    10.4.4 Key Developments

    10.4.5 SWOT Analysis

    10.4.5 Key Strategies

    10.5 Azevan Pharmaceuticals

    10.5.1 Company Overview

    10.5.2 Financial Overview

    10.5.3 Products Offered

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.5.6 Key Strategies

    10.6 Marinus Pharmaceuticals, Inc.

    10.6.1 Company Overview

    10.6.2 Financial Overview

    10.6.3 Products Offered

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.6.6 Key Strategies

    10.7 Tonix Pharmaceuticals Holding Corp.

    10.7.1 Company Overview

    10.7.2 Financial Overview

    10.7.3 Products Offered

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.7.6 Key Strategies

    10.8 Bionomics

    10.8.1 Company Overview

    10.8.2 Financial Overview

    10.8.3 Products Offered

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.8.6 Key Strategies

    10.9 Greenstone LLC

    10.9.1 Company Overview

    10.9.2 Financial Overview

    10.9.3 Products Offered

    10.9.4 Key Developments

    10.9.5 SWOT Analysis

    10.9.6 Key Strategies

    10.10 Mylan NV

    10.10.1 Company Overview

    10.10.2 Financial Overview

    10.10.3 Products Offered

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.10.6 Key Strategies

    10.11 Others

    Chapter 11. Appendix

    11.1. References

    11.2. Related Reports


    LIST OF TABLES

    Table 1 Global Post-Traumatic Stress Disorder (PTSD) Treatment Synopsis, 2020–2025

    Table 2 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Estimates & Forecast, 2020-2027, (USD Million)

    Table 3 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 6 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 8 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 9 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 10 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 11 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 12 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 13 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 14 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 15 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 16 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 17 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 18 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 19 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 20 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 21 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 22 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 23 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation of the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

    Figure 3 Market Dynamics for the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

    Figure 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Treatment, 2020

    Figure 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by End User, 2020

    Figure 6 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2020

    Figure 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2020

    Figure 8 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 9 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 10 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 13 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market: Company Share Analysis, 2020 (%)

    Figure 14 GlaxoSmithKline: Key Financials

    Figure 15 GlaxoSmithKline: Segmental Revenue

    Figure 16 GlaxoSmithKline: Regional Revenue

    Figure 17 Pfizer: Key Financials

    Figure 18 Pfizer: Segmental Revenue

    Figure 19 Pfizer: Regional Revenue

    Figure 20 Eli Lilly and Company: Key Financials

    Figure 21 Eli Lilly and Company: Segmental Revenue

    Figure 22 Eli Lilly and Company: Regional Revenue

    Figure 23 H. Lundbeck A/S: Key Financials

    Figure 24 H. Lundbeck A/S: Segmental Revenue

    Figure 25 H. Lundbeck A/S: Regional Revenue

    Figure 26 Azevan Pharmaceuticals: Key Financials

    Figure 27 Azevan Pharmaceuticals: Regional Revenue

    Figure 28 Azevan Pharmaceuticals: Key Financials

    Figure 29 Marinus Pharmaceuticals, Inc.: Segmental Revenue

    Figure 30 Marinus Pharmaceuticals, Inc.: Regional Revenue

    Figure 31 Marinus Pharmaceuticals, Inc.: Key Financials

    Figure 32 Tonix Pharmaceuticals Holding Corp.: Segmental Revenue

    Figure 33 Tonix Pharmaceuticals Holding Corp.: Regional Revenue

    Figure 34 Tonix Pharmaceuticals Holding Corp.: Key Financials

    Figure 35 Bionomics: Segmental Revenue

    Figure 36 Bionomics: Regional Revenue

    Figure 37 Bionomics: Key Financials

    Figure 38 Greenstone LLC: Segmental Revenue

    Figure 39 Greenstone LLC: Regional Revenue

    Figure 40 Greenstone LLC: Key Financials

    Figure 41 Mylan NV: Segmental Revenue

    Figure 42 Mylan NV: Regional Revenue

    Figure 43 Mylan NV: Key Financials




    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.